The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...

Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically planning ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

SALZBURG, Austria--(BUSINESS WIRE)--Launched as the D-mine ® Pump, this portable micro infusion device recently received European CE approval and is currently being launched in several European ...

SALZBURG, Austria--(BUSINESS WIRE)--After successfully launching the D-mine ® Pump, an infusion device designed to provide precise continuous subcutaneous drug delivery for Parkinson´s patients, EVER ...